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Abstract Mantle cell lymphomas (MCL), characterized by
the t(11;14)(q13;q32), frequently carry secondary genetic
alterations such as deletions in chromosome 17p involving
the TP53 locus. Given that the association between TP53-
deletions and concurrent mutations of the remaining allele
is weak and based on our recent report that the Hyper-
methylated in Cancer 1 (HIC1) gene, that is located
telomeric to the TP53 gene, may be targeted by deletions
in 17p in diffuse large B-cell lymphoma (DLBCL), we
investigated whether HIC1 inactivations might also occur in
MCL. Monoallelic deletions of the TP53 locus were detected
in 18 out of 59 MCL (31%), while overexpression of p53
protein occurred in only 8 out of 18 of these MCL (44%). In
TP53-deleted MCL, the HIC1 gene locus was co-deleted in
11 out of 18 cases (61%). However, neither TP53 nor HIC1
deletions did affect survival of MCL patients. In most
analyzed cases, no hypermethylation of the HIC1 exon 1A
promoter was observed (17 out of 20, 85%). However, in
MCL cell lines without HIC1-hypermethylation, the mRNA
expression levels of HIC1 were nevertheless significantly
reduced, when compared to reactive lymph node specimens,
pointing to the occurrence of mechanisms other than epigenetic
or genetic events for the inactivation of HIC1 in this entity.
Keywords Mantlecelllymphoma.del(17p).TP53.HIC1
Introduction
Mantle cell lymphoma (MCL), an aggressive subtype of B-
cell non-Hodgkin lymphomas (B-NHL), comprises 5–10%
of human B-cell lymphomas approximately [1]. The
clinical course is heterogeneous, with survival times
ranging from a few months to more than 10 years [2–4].
The hallmark genetic feature of this neoplasm is the
translocation t(11;14)(q13;q32) that juxtaposes the cyclin
D1 gene and the enhancer region of the immunoglobulin
heavy chain genes, leading to constitutive overexpression
of cyclin D1 [5–8]. Although the deregulation of cyclin D1
is thought to be the primary genetic alteration in the
pathogenesis of MCL, additional oncogenic events are
required to promote tumor progression [9]. Various studies
that applied genome-wide techniques to unravel secondary
chromosomal aberrations in MCL, resulted in the charac-
terization of frequently deleted regions and subsequently in
the identification of particular tumor suppressor genes (e.g.,
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One critical tumor suppressor gene that is frequently
targeted by deletions in the short arm of chromosome 17 is
the transcription factor TP53. In MCL, TP53 gene deletions
are almost invariably associated with a loss of the whole
arm of chromosome 17p [7, 10, 12]. Whether, therefore, loss
of the TP53 locus represents the most important biological
consequence of 17p deletions in MCL, remains unknown.
We recently reported that the tumor suppressor candidate
Hypermethylated in Cancer 1 (HIC1), which is located in
the chromosome band 17p13.3 telomeric to the TP53 locus,
is frequently inactivated by concurrent deletion and pro-
moter hypermethylation in diffuse large B-cell lymphoma
(DLBCL) [16]. To investigate whether inactivation of HIC1
also occurs in MCL, we performed a detailed analysis of the
chromosome 17p deletion status on the basis of conven-
tional cytogenetic analysis, fluorescence in situ hybridiza-
tion (FISH), polymerase chain reaction (PCR)-based loss of
heterozygosity (LOH) analysis, and quantitative real-time
(RT-qPCR) approaches. Our results demonstrate that HIC1,
although frequently co-deleted with TP53 in 17p13.3, is—in
contrast to DLBCL—infrequently hypermethylated in MCL
suggesting that deletions of 17p might have different
biological consequences in MCL and DLBCL.
Material and methods
Tumor specimens and cell lines
Fifty-nine MCL specimens, referred to the Institute of
Pathology, University of Würzburg, were classified accord-
ing to the criteria of the World Health Organization (WHO)
classification system [17]. Cyclin D1 overexpression or the
presence of the t(11;14)(q13;q32) were identified in all
cases by immunohistochemistry or FISH analysis, respec-
tively. Genomic DNA was extracted from formalin-fixed
and paraffin-embedded tissue (7 out of 59), from fresh-
frozen tissue (18 out of 59), and from leukemic blood
specimens (34 out of 59) as previously described [16, 18].
Among these 59 MCL patients, 47 were male and 12
female. The median age at diagnosis was 66 years (range
48 to 97 years), and median survival was 2.2 years. Of 59
MCL, 45 tumors were obtained at the time of primary
diagnosis, while 14 lymphoma samples were relapsed
MCL. Our study was approved by the local Ethics
Committee of the University of Würzburg, Germany. The
therapy was heterogeneous but, in most patients CHOP-
based (without addition of Rituximab).
The human MCL cell lines used in this study were
GRANTA-519, HBL2, MINO, REC1, and JVM2. All cell
lines were obtained from the German Collection of Micro-
organisms and Cell Cultures (DSMZ, Braunschweig, Ger-
many) and were maintained in Roswell Park Memorial
Institute-1640 cell culture medium (PAA, Pasching, Austria)
supplemented with 10% fetal calf serum (PAA, Pasching,
Austria). DNA and RNA were extracted using the AllPrep
DNA/RNA Mini Kit (Qiagen, Hilden, Germany) according
the manufacturer’s protocol.
Chromosome banding analysis
Chromosome spreads were prepared from lymphocyte
short-term cultures in 46 of 59 MCL cases according to
standard protocols [19]. After Giemsa–trypsin banding, the
karyotypes were established according to the International
System for Human Cytogenetic Nomenclature (ISCN) [20].
Identical structural aberrations, or genetic gains, in two or
more metaphases and identical genetic losses in at least
three metaphases were defined as clonal.
Immunohistochemistry
Immunohistochemical staining for the p53 protein was
assessed on freshly cut slides from formalin-fixed and
paraffin-embedded tissues using the DO-7 antibody (1:50;
DAKO, Glostrup, Denmark), as previously reported [21].
The staining for p53 was considered positive when ≥20%
of tumor cells showed strong nuclear reactivity.
Interphase fluorescence in situ hybridization
InterphaseFISHwithTP53- and HIC1-locus-specific probes,
using BAC clones RP11-199F11 and RP11-667K14, re-
spectively, was performed according to previously published
protocols [16]. The BAC clones were obtained from the
libraries RPCIB753 and RPCIP704 of the RZPD German
Resource Center for Genome Research (Berlin, Germany).
To determine the cutoff level for each probe, control
studieswithfivereactivelymphnodespecimenswerecarried
out. The cutoff ratios for RP11-199F11 and RP11-667K14
were 11.7% and 11.8%, respectively. Signal visualization of
at least 100 intact nuclei per case was accomplished on a
Leica fluorescence microscope (Leica Microsystems, Ben-
sheim, Germany). Illustrations were documented using the
ISISimagingsystem (MetaSystems, Altlussheim, Germany).
Real-time quantitative PCR
To detect genomic losses of the HIC1 and TP53 loci in the
tumor specimens, RT-qPCR using genomic DNA was
performed as previously described [16]. All measurements
were done in triplicates. Presence or loss of the genomic
HIC1 or TP53 region was defined relative to the β-2-
86 J Hematopathol (2008) 1:85–95microglobulin (B2M) locus (15q21) and calculated with the
standard curve method using DNA prepared from peripheral
blood mononuclear cells of healthy volunteers. The cutoff
ratios for deletion were determined by analyzing DNA of
five reactive lymph nodes. The cutoff ratios for HIC1/B2M
and TP53/B2M were 0.74 and 0.76, respectively.
HIC1 mRNA expression was determined by TaqMan
qRT-PCR. Reverse transcription of 1 μg total RNA was
carried out using the High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems, Foster City, CA,
USA). qRT-PCR was performed with the ABI PRISM 7700
Sequence Detection System (Applied Biosystems). All
measurements were done in triplicates and calculated with
the standard curve method using cDNA of reactive lymph
node specimen and β-Actin as endogenous control. Primers
for HIC1 amplification were 5′-CTGGATCCGCCGT
CAGC-3′ (sense) and 5′- TGTCCAGCATCGTCTGC-3′
(antisense). To amplify β-Actin, the following oligonu-
cleotides were used: 5′-GACGAGGGCGTGCTGGT
GGG-3′ (sense) and 5′-GATGCCTCTCTTGCTCTGGGC-
3′ (antisense).
LOH analysis
Normal and tumor DNA were analyzed for loss of het-
erozygosity (LOH) of the TP53 (D17S1678) and HIC1
(D17S831) gene loci as previously reported [18].
Methylation analysis of HIC1
DNA was bisulphite-modified as previously described [18].
Methylation-specific PCR (MSP) was carried out according
to published protocols [22]. Primers used to amplify the 5′-
untranslated region (exon 1A) of the HIC1 gene were also
reported previously [16].
Statistical analysis
The Kaplan–Meier method was used to estimate overall
survival of the patients. The statistical significance of asso-
ciations between the TP53 or HIC1 status and survival was
determined by using the log rank test. A p value of <0.05 was
considered statistically significant. For all analyses, the SPSS
software V12.0 (SPSS, Chicago, IL, USA) was used.
Results
Deletions of the TP53 gene locus are not strictly associated
with altered p53 protein expression
To define the deletion status of TP53 in the chromosome
band 17p13.1, fluorescence in situ hybridization (FISH)
with the TP53-locus-specific probe RP11-199F11 was
performed in 51 out of 59 MCL cases. In addition, tumor
and normal DNA of 24 out of 59 MCL could be analyzed
for loss of heterozygosity (LOH) of TP53 using the
microsatellite marker D17S1678. A monoallelic deletion
of the TP53 gene was observed in 18 out of 59 MCL (31%)
(Table 1).
In conventional cytogenetic analyses of 46 out of 59
MCL, a deletion in the short arm of chromosome 17 [del
(17p)] corresponded with loss of the TP53 gene in 6 out of
18 samples, while in 8 out of 18 tumors, the monoallelic
TP53-deletion, as detected by FISH and/or LOH, was not
visible by chromosome banding. In four cases that harbored
a deletion of the TP53-locus by FISH, no banding analyses
were available (Table 1). Interestingly, conventional cyto-
genetic analysis revealed a del(17p) in two MCL, without
affecting the TP53 locus as shown by FISH and LOH
(Table 1).
To check for possible inactivating mutations of the
second, non-deleted TP53 allele, we performed immuno-
histochemical staining of the p53 protein in 51 of 59 cases.
An overexpression of the p53 protein was detected in 18
out of 51 MCL. Whereas eight of these cases harbored
TP53 gene deletions, in the remaining ten MCL samples,
accumulation of p53 protein occurred without
corresponding deletion of the TP53 locus. Vice versa, no
p53 overexpression was observed in 33 of 51 MCL. Of
those, 25 MCL did not harbor a deletion of the TP53 gene,
while in 8 out of 33 tumors, a monoallelic TP53-deletion
was detected (Table 1). Focusing on the eight MCL
harboring a TP53 deletion without detectable p53 over-
expression, three of these cases carried a del(17p) by
conventional cytogenetic analysis, while in three additional
tumors, a del(17p) was not visible by chromosome banding.
In the remaining two MCL, no chromosome banding data
was available, and the TP53 deletion was defined only on
the basis of FISH and LOH analyses (Table 1).
In summary, deletion of the TP53 locus in concert with
overexpression of p53 protein suggesting p53 inactivation
was evident in 8 of 59 MCL (14%). Of note, in 3 of 8 MCL
a del(17p), as indicated by conventional cytogenetic analy-
sis, was not associated with overexpression of p53-protein.
Moreover, in 2/59 MCL samples a del(17p) occurred
without affecting the TP53-locus, pointing to the existence
of another tumor suppressor gene in chromosome 17p.
Deletion of Hypermethylated in Cancer 1 (HIC1) gene
in the chromosome band 17p13.3 occurs in addition
to the loss of TP53 gene locus in MCL
Because we had observed an inactivation of HIC1 by
monoallelic deletion and concurrent promoter hypermethy-
lation of the remaining allele in diffuse large B-cell
J Hematopathol (2008) 1:85–95 87T
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J Hematopathol (2008) 1:85–95 89lymphomas (DLBCL) [16], we examined, whether the
deletion of HIC1, located in the chromosome band 17p13.3
telomeric to TP53, might also be associated with the
pathogenesis of MCL.
The deletion status of HIC1 was examined in 59 MCL,
using FISH with the HIC1 locus-specific probe RP11-
667K14 (in 32 out of 59 fresh-frozen and leukemic blood
samples) or LOH analysis with the microsatellite marker
D17S831 (on DNA from 10/59 MCL samples extracted
from leukemic blood) or by using both methods when
appropriate material was available (in 17 out of 59 MCL).
A monoallelic deletion of RP11-667K14 by FISH and/or
loss of heterozygosity of D17S831 by LOH analysis was
observed in 18 out of 59 cases (31%) (Table 1). Deletion of
both the HIC1 and TP53 loci simultaneously occurred in
only 11 of these MCL. By conventional cytogenetic
analysis, a del(17p) was detected in 4 out of 11 MCL
samples, indicating complete loss of chromosome 17p in
these cases (Table 1, Fig. 1a–c).
In 7 out of 18 HIC1-deleted MCL, no loss of the TP53
gene was observed. Two of these cases were shown to
harbor a del(17p) by cytogenetic analysis without concom-
itant loss of the TP53 locus, indicating a del(17p), with a
breakpoint telomeric to the chromosome band 17p13.1,
harboring the TP53 locus (Table 1, Fig. 1a,f–g).
In 41 out of 59 MCL, no deletion of HIC1 was detected,
but seven of these cases carried a monoallelic TP53
deletion. Two of these MCL cases harbored a del(17p) by
conventional cytogenetics, which suggests a deletion of
chromosome 17p, excluding the telomeric part of the region
containing the HIC1 gene (Table 1, Fig. 1a,d–e).
To validate the deletion pattern of HIC1 and TP53 with an
alternative technique, we used quantitative PCR (qPCR) in
33 MCL to determine the HIC1 and TP53 deletion status in
correlation to the reference gene beta-2-microglobulin
(B2M). By this approach, 22 of 33 samples were shown to
harbor a normal TP53 and HIC1 status, as indicated by
HIC1/B2M and TP53/B2M ratios ranging between 0.95 and
1.06, comparable to the results of FISH and LOH experi-
ments (Table 1, Fig. 2). Monoallelic deletion of the TP53
gene without loss of the HIC1 locus was observed in 3 out of
33 MCL (nos. 19, 25 and 51) by qPCR (Table 1, Fig. 2). In 5
out of 33 tumors (nos. 12, 15, 17, 49 and 55), which
exhibited one FISH signal with the HIC1-specific probe,
HIC1 deletion was observed by qPCR, as indicated by HIC1/
B2M ratios between 0.19 and 0.31, while a normal status was
detected for the TP53 gene (Table 1,F i g .2). A concurrent
deletion of both the HIC1 and TP53 gene loci was found in 3
out of 33 MCL (nos. 3, 6, and 45), confirming the results of
FISH and LOH experiments (Table 1, Fig. 2).
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Fig. 1 Chromosome 17p deletions in MCL. Whole arm deletion of
chromosome 17p, including TP53 and HIC1, in 11/59 MCL (a), as
indicated by fluorescence in situ hybridization using the TP53-specific
probe RP11-199F11 (green) and the HIC1-specific probe RP11-
667K14 (red)( b–c). Partial deletion of chromosome band 17p13.1
to 17p13.3 including only the TP53-locus in 7 out of 59 MCL (a), as
seen by loss of one green signal (TP53) in contrast to two HIC1-
signals (red)( d–e). Deletion of chromosomal band 17p13.3, including
HIC1 without loss of TP53 in 7/59 MCL (a), as indicated by one
HIC1-signal (red) instead of two TP53-signals (green; f–g)
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is not associated with hypermethylation of the HIC1
promoter
Because monoallelic deletion of the HIC1 gene was
previously described to be associated with promoter
methylation of the remaining HIC1 allele in DLBCL [16],
we investigated the HIC1 exon 1A promoter in a subset of
MCL. Hypermethylation of exon 1A, which codes for the 5′
untranslated region of the transcript, has been described as
a mechanism for HIC1 gene inactivation in mouse
lymphomas, and in human tumors and was associated with
decreased HIC1 mRNA expression [23–25].
Because leukemic involvement is frequent in MCL [26],
we preferentially focused on the analysis of DNA extracted
from leukemic peripheral blood of 20 MCL patients, which
facilitates the comparison of the HIC1 methylation status
between malignant MCL cells and normal granulocytes.
Three MCL (nos. 21, 27, 31; 15%) showed aberrant HIC1-
methylation in the tumor DNA, in contrast to DNA obtained
from granulocytes of the same patient sample (Fig. 3a,
Table 1). In only one of these cases, HIC1 methylation was
associated with a concomitant deletion of the HIC1 locus
(Table 1). In 14 out of 20 cases (70%), no alteration of exon
1A promoter methylation was observed in the lymphocyte
DNA when compared to DNA from nonmalignant granulo-
cytes. The majority of these cases showed unmethylated
DNA in both normal and tumor cells (in 8 out of 14 cases,
Fig. 3b, Table 1), while weakly methylated DNA of both
tumor and normal cells was detected in 6 out of 14 MCL
(Fig. 3c, Table 1). In 3 out of 20 cases (15%), HIC1
methylation was observed in DNA of granulocytes, while in
lymphocytes from the same patient, the HIC1-promoter
appeared to be less methylated (Fig. 3d, Table 1).
To ensure that the epigenetic HIC1 profile of MCL cells
in leukemic peripheral blood reflects that obtained from
MCL cells in lymph nodes, we analyzed DNA extracted
from lymph node specimens in addition to the leukemic
peripheral blood in 3 out of 20 cases. No differences in the
HIC1 methylation status were observed when comparing
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Fig. 2 Genomic deletions of the HIC1 and TP53 loci detected by
quantitative real-time PCR. Three reactive lymph node samples show
HIC1/B2M and TP53/B2M ratios close to 1, indicating wild type
configuration of both loci (LN1–LN3, grey), as also presented for
MCL no. 41 (light blue). Two MCL (nos. 12, 49) show a HIC1/B2M
ratio below the cutoff level indicating a deletion of the HIC1 locus,
while the TP53/B2M ratio indicates wild-type configuration of the
TP53 locus (dark blue). Two MCL (nos. 25, 51) show evidence of a
TP53 deletion in the presence of two copies of HIC1 (light green).
One MCL (no. 3) harbors a co-deletion of the HIC1 and TP53 loci
(dark green)
Normal Tumor
AB C
MCL #21 MCL #55 MCL #33 MCL #20
UM MU UM MU U M MU U M MU
118 bp
95 bp
Normal Tumor Normal Tumor Normal Tumor
D
Fig. 3 Methylation-specific PCR of the 5′-UTR of HIC1 in
granulocytes (normal) and lymphocytes (tumor) of MCL patients.
Samples containing methylated DNA produced PCR amplicons with
the M (methylated) primer set, while samples without methylation
yielded PCR products when the U (unmethylated) primer set was
applied. Promoter methylation of HIC1 in tumor cells, while normal
cells showed unmethylated HIC1-sequence in MCL no. 21 (a).
Neither normal, nor tumor cells harbored methylated DNA product
in MCL no. 55 (b). Slightly methylated DNA in normal and tumor
cells in MCL no. 33 (c). Methylation of the HIC1-promoter in normal,
but not in tumor cells in MCL no. 20 (d)
J Hematopathol (2008) 1:85–95 91DNA extracted from lymph node and peripheral blood in
these MCL (data not shown).
Reduced HIC1 mRNA levels in MCL cell lines
are not associated with promoter hypermethylation
To investigate the possible role of HIC1 in MCL pathogen-
esis in more detail, we studied the five MCL cell lines
GRANTA-519, HBL2, MINO, REC1, JVM2, first, to
determine the methylation status of HIC1 and, second, to
assess HIC1 gene expression level. It has to be emphasized
that none of the cell lines harbor homozygous deletion of
chromosome 17p, as assessed by 500K SNP array analysis
(E. Hartmann, unpublished data). While GRANTA-519,
HBL2, and MINO presented with monoallelic deletions in
the short arm of chromosome 17, including TP53 and HIC1
gene locus, REC1 and JVM2 showed a normal diploid status
of 17p. None of the cell lines presented with an aberrant
methylation of the HIC1 exon 1A promoter, comparable to
those results obtained from reactive lymph node specimens
and in the majority of the primary MCL tumors (Fig. 4a).
However, expression levels of HIC1 mRNA were signifi-
cantly reduced in MCL cell lines, in contrast to the normal
lymphoid tissue samples (p=0.001, Fig. 4b).
Monoallelic deletion of the HIC1 locus is not associated
with survival of MCL patients
HIC1 and TP53 inactivations have recently been reported to
be negative prognostic markers in diffuse large B-cell
lymphoma. To analyze the clinical course of MCL patients
according to their HIC1 and TP53 status, we compared the
patients’ survival data of 34 out of 59 cases with a deletion
of either HIC1 or TP53, as well as of MCL patients with
overexpression of p53 protein. Given the caveat of a small
patient series, neither TP53 deletions nor deletions of the
HIC1 gene locus were associated with inferior survival of
MCL patients (Fig. 5a,c). Overexpression of p53 protein,
however, clearly predicted for inferior outcome compared
to tumors from MCL patients lacking expression of the
protein (p≤0.0001, Fig. 5b).
Discussion
MCL is a well-defined subtype of B-cell non-Hodgkin
lymphoma, characterized by the translocation t(11;14)(q13;
q32), which is present in virtually all cases. In addition to
this translocation, MCL tumor cells harbor various second-
ary chromosomal alterations [27]. One critical regulator of
cell survival is the tumor suppressor gene TP53, located in
chromosome band 17p13.1, a genomic region frequently
deleted in MCL [7]. On the basis of the two-hit hypothesis,
the inactivation of a tumor suppressor gene, e.g., by
concurrent deletion and mutation/hypermethylation of the
second allele, is considered a prerequisite for tumor
progression [28, 29]. The association of TP53 gene
deletions and mutation of the remaining non-deleted
TP53-allele, however, has been reported to be only weak
in MCL [30, 31]. This is also confirmed in our series, in
which 18 out of 59 MCL (31%) harbored a monoallelic
TP53 deletion, while only eight of these cases (44%)
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92 J Hematopathol (2008) 1:85–95showed an overexpression of p53 protein suggesting the
inactivation of the remaining TP53 allele by gene mutation.
The finding that 10 out of 18 MCL showed monoallelic
TP53 deletions without concomitant overexpression of p53
protein might be pointing to the existence of another
candidate tumor suppressor gene on chromosome 17p in
MCL. Because no mutational analysis of the TP53 gene had
been performed in this study, we cannot entirely exclude the
occurrence of complete TP53 inactivation in these cases by
immunohistochemical analysis of p53 protein expression,
given its false-negative results, especially in the context of
non-sense and truncating mutations of the TP53 gene [32,
33]. However, we consider it unlikely that this scenario
accounts for the lack of p53 protein expression in the
majority of cases, as most of the TP53 mutations occurring
in MCL are missense mutations which do not result in
truncated p53 protein [34, 35]. In addition, it has been
reported that discordances between the results of p53
immunohistochemistry and mutational analysis of the
TP53 gene can also be due to alternative mechanisms of
p53 stabilization, leading to overexpression of p53 protein
without concomitant TP53 gene mutation. In contrast, none
of the previously published MCL cases lacking p53-over-
expression showed mutation of the TP53 gene [34–36].
In addition to ten MCL that harbored monoallelic TP53
deletions without concurrent overexpression of p53 protein
in our series, a deletion of the short arm of chromosome 17
was detected in two MCL, without affecting the TP53 gene
locus. This finding points to the loss of genomic material
telomeric to the TP53 locus, possibly inactivating other
tumor suppressor genes, which is consistent with the
previous finding of novel recurrently deleted regions in
17p13.3, as reported for MCL [37], but also for DLBCL
[16] and various leukemia subtypes [38]. These findings
provide support for the hypothesis that genomic deletions
involving the chromosomal band 17p13 may not always
affect TP53 itself and raises the question whether other
tumor suppressor genes might be targeted by deletions in
this genomic region. The chromosomal band 17p13.3
harbors several candidate genes, such as LOST1, DPH2L1,
OVCA2, MNT/ROX,o rHIC1, which had been described to
be altered in various cancer types [39–42]. Because the
tumor suppressor candidate HIC1 had previously been
reported to be frequently inactivated in DLBCL [16], as
well as in acute lymphocytic leukemia, in chronic myelog-
enous leukemia [43], and in acute myeloid leukemia [44],
we focused our investigation in MCL on this candidate.
Monoallelic deletion of the HIC1 gene was observed in
18 out of 59 MCL analyzed. Interestingly, HIC1 deletions
were detected in 7 out of these 18 cases that did not show
evidence of a concurrent genomic loss of the TP53 locus.
Two of these cases harbored a del(17p), as indicated by
cytogenetic analyses, suggesting a partial deletion of
chromosome 17p telomeric to TP53 gene, as had been
recently described in DLBCL [16], as well as in myeloid
and lymphoid leukemia [38].
Because HIC1 has been reported to be frequently
inactivated by promoter hypermethylation, but not by
mutation [23, 42], we focused our investigation on the
methylation status. However, methylation of the HIC1 exon
1A promoter was only rarely encountered in MCL, in
contrast to our previous findings in DLBCL [16]. The lack
of HIC1 hypermethylation in the MCL cell lines GRANTA-
519, HBL2, MINO, JVM2, and REC1 further supports our
findings that aberrant promoter methylation of HIC1 is an
infrequent event in MCL. Nevertheless, the mRNA expres-
sion levels of HIC1 were significantly reduced in the MCL
cell lines studied when compared to those observed in
reactive lymphoid tissues, indicating that the inactivation of
HIC1 is not necessarily correlated with epigenetic or
genetic events affecting the gene locus, but may be due to
alternative mechanisms of HIC1 inactivation. Of note, the
reduction of HIC1 mRNA expression, independent of HIC1
promoter hypermethylation, has been recently reported in
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Fig. 5 Survival analysis of MCL patients according to the TP53 and
HIC1 status. Kaplan–Meier survival curves for patients with mono-
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J Hematopathol (2008) 1:85–95 93hematological malignancies [45]. In keeping with previous
findings about a possible role of HIC1 in the differentiation
of solid tumors, Britschgi et al. reported a decrease of HIC1
expression level in primary human acute myeloid leukae-
mia (AML) when compared with terminally differentiated
granulocytes. Although the mechanism by which HIC1 is
inactivated may not be related to genetic or epigenetic
alterations, Britschgi and colleagues suggested that the
repression of retinoic acid receptor signaling in leukaemia
possibly causes downregulation of HIC1 mRNA expression
[45].
Although not epigenetically inactivated, the MCL subset
studied here presented with a high proportion of mono-
allelic deletions of the HIC1 gene locus. The heterozygous
loss of HIC1 function in mice has been reported to result in
earlier tumor formation and increased aggressiveness in
TP53-altered mice [46], and a potential synergistic effect of
TP53 and HIC1 inactivation with respect to clinical
outcome could be demonstrated in DLBCL patients [16].
Although limited by the small number of cases and the
heterogenous treatment of MCL patients, neither the
deletion of HIC1 nor the deletion of TP53 was associated
with inferior overall survival. These results are in line with
previous reports described for loss of TP53 [31] as well as
for 17p deletions in MCL in general [10, 12, 15]. In
contrast, deletion of chromosome 17p has also been reported
to be of prognostic value in B-NHL [47] and specifically in
MCL [11]. Because deletions of the TP53 or the HIC1 gene
locus alone were not associated with the clinical outcome of
MCL patients in our study, we cannot entirely exclude the
presence of other tumor-relevant candidate genes in chro-
mosome 17p, beyond TP53 and HIC1.
Interestingly, overexpression of p53 by immunohisto-
chemistry, possibly indicating an underlying TP53 gene
mutation, was associated with significantly shorter overall
survival of MCL patients in our series in accordance with
reports about TP53 mutations in MCL [34, 35]. The
impaired survival of MCL patients with tumors showing
overexpression of p53 protein may therefore be explained
by the dominant-negative effect of TP53-mutations that
may drive the remaining wild-type p53 into the mutant
conformation resulting in a complete TP53 inactivation
[48].
In conclusion, our study provides further evidence that
deletions in chromosome 17p are only weakly correlated
with overexpression of p53 protein, indicating that the TP53
gene may not be the only target of this genomic alteration.
Although we demonstrate that in a subset of MCL,
chromosome 17p deletions affect the genomic region
around the HIC1 locus, the inactivation of HIC1 by
promoter methylation of exon 1A was only infrequently
observed in MCL. However, in MCL cell lines without
hypermethylation of the HIC1 promoter, the mRNA
expression levels were significantly reduced, indicating
alternative mechanisms for the inactivation of HIC1 in this
tumor. Because reexpression of HIC1 was shown to be
feasible in AML with downregulated HIC1 mRNA [45], it
will be of interest to study a possible benefit of MCL
patients restoring HIC1 function.
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